Sugi Predict

Sugi Predict / Compounds / SCHEMBL281586

SCHEMBL281586

SCHEMBL281586

COc1cccc2c1C(=O)C(=O)N2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CES1 P23141 2/20 0.55
▸ TGM2 P21980 2/20 0.49
▸ NPC1 O15118 1/20 0.45
▸ KMT2A Q03164 4/20 0.45
▸ MEN1 O00255 3/20 0.45
▸ CA1 P00915 1/20 0.45
▸ CA2 P00918 1/20 0.45
▸ CA7 P43166 1/20 0.45
▸ CA9 Q16790 1/20 0.45
▸ CASP3 P42574 1/20 0.45
▸ TOP1 P11387 1/20 0.44
▸ CHEK1 O14757 2/20 0.44
▸ ALDH1A1 P00352 4/20 0.44
▸ MAPT P10636 4/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ USP2 O75604 1/20 0.44
▸ DUSP3 P51452 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ HTT P42858 2/20 0.44
▸ APAF1 O14727 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30397534 1.00 CES1 (0.55) CES1TGM2NPC1KMT2AMEN1
SCHEMBL21623878 0.85 KMT2A (0.45) TGM2NPC1KMT2AMEN1CA1
SCHEMBL21623877 0.85 KMT2A (0.45) TGM2NPC1KMT2AMEN1CA1
SCHEMBL5894111 0.81 CES1 (0.50) CES1TGM2KMT2AMEN1CA1
SCHEMBL5733129 0.80 BRD4 (0.45) TGM2NPC1KMT2AMEN1CA1
SCHEMBL4625091 0.77 CES1 (0.50) CES1TGM2KMT2AMEN1CASP3
SCHEMBL30504154 0.77 CES1 (0.50) CES1TGM2CA1CA2KDM4E
SCHEMBL2305964 0.76 RAB9A (0.47) CES1NPC1KMT2AMEN1CA1
SCHEMBL5329280 0.75 CES1 (0.61) CES1TGM2KMT2AMEN1CA1
SCHEMBL7815590 0.75 ALDH1A1 (0.44) CES1TGM2KMT2AMEN1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12421191-B2 3-hydroxyoxindole derivatives as CRHR2 antagonist RAQUALIA PHARMA INC. (JP) 2025-09-23 — — US disclosed
US-20240158368-A1 Pyrrolidine Main Protease Inhibitors as Antiviral Agents ABBVIE INC. (US) 2024-05-16 — — US disclosed
WO-2024081351-A1 PYRROLIDINE MAIN PROTEASE INHIBITORS AS ANTIVIRAL AGENTS ABBVIE INC. (US) 2024-04-18 — — WO disclosed
US-11952365-B2 Anti-viral compounds ALIGOS THERAPEUTICS, INC. (US) 2024-04-09 — — US disclosed
US-20240018103-A1 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST RAQUALIA PHARMA INC. (JP) 2024-01-18 — — US disclosed
EP-4222142-A1 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST RaQualia Pharma Inc. (JP) 2023-08-09 — — EP disclosed
CN-116096714-A Antiviral compounds for the treatment of coronavirus, picornavirus and norovirus infections 安力高医药股份有限公司 2023-05-09 — — CN disclosed
EP-4165037-A1 ANTI-VIRAL COMPOUNDS FOR TREATING CORONAVIRUS, PICORNAVIRUS, AND NOROVIRUS INFECTIONS Aligos Therapeutics, Inc. (US) 2023-04-19 — — EP disclosed
WO-2022071484-A1 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST RAQUALIA PHARMA INC. (JP) 2022-04-07 — — WO disclosed
CN-111072546-B Synthesis method of 5-ethynylindoline-2, 3-diketone 阿里生物新材料（常州）有限公司 2022-03-11 — — CN disclosed
US-20060079520-A1 Sulfonamide peri-substituted bicyclics for occlusive artery disease SAGA INVESTMENTS LLC 2006-04-13 — — US disclosed
US-20050054713-A1 3-Substituted oxindole beta3 agonists JESUDASON CYNTHIA DARSHINI (US) 2005-03-10 — — US disclosed
US-6825220-B2 INVOLVES THE RELATIONSHIP BETWEEN ADRENERGIC RECEPTOR STIMULATION AND ANTI-HYPERGLYCEMIC EFFECTS ELI LILLY AND COMPANY 2004-11-30 — — US disclosed
US-20040097532-A1 3-Substituted oxindole beta 3 agonists ELI LILLY AND COMPANY 2004-05-20 — — US disclosed
EP-1341759-A2 3-SUBSTITUTED OXINDOLE BETA 3 AGONISTS ELI LILLY AND COMPANY (US) 2003-09-10 — — EP disclosed
WO-2002038543-A2 3-SUBSTITUTED OXINDOLE BETA 3 AGONISTS ELI LILLY AND COMPANY (US) 2002-05-16 — — WO disclosed
WO-2002038544-A2 3-SUBSTITUTED OXINDOLE BETA 3 AGONISTS ELI LILLY AND COMPANY (US) 2002-05-16 — — WO disclosed
EP-0731091-B1 2-OXOINDOLINE DERIVATIVES AS CHOLECYSTOKININ RECEPTOR ANTAGONISTS TANABE SEIYAKU CO (JP) 2002-01-02 — — EP disclosed
US-5807883-A GASTROINTESTINAL DISORDERS; PANCREATITIS TANABE SEIYAKU CO., LTD. (JP) 1998-09-15 — — US disclosed
EP-0731091-A1 2-OXOINDOLINE DERIVATIVE TANABE SEIYAKU CO., LTD. (JP) 1996-09-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018103-A1 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST CRHR2, CRHR1, CRH CES1 1763/4885TGM2 3605/4885NPC1 2853/4885
US-11952365-B2 Anti-viral compounds EIF2AK2, ZC3HAV1, HAVCR2 CES1 705/4885TGM2 3037/4885NPC1 34/4885
US-20050054713-A1 3-Substituted oxindole beta3 agonists ADRB3, ADRB2, ADRB1 CES1 2077/4885TGM2 4152/4885NPC1 2482/4885
US-12421191-B2 3-hydroxyoxindole derivatives as CRHR2 antagonist CRHR2, CRHR1, CRH CES1 1763/4885TGM2 3605/4885NPC1 2853/4885
US-20060079520-A1 Sulfonamide peri-substituted bicyclics for occlusive artery disease PTGIS, PTGIR, PTGS2 CES1 490/4885TGM2 1035/4885NPC1 3060/4885
US-20240158368-A1 Pyrrolidine Main Protease Inhibitors as Antiviral Agents PREP, PEPD, DNPEP CES1 810/4885TGM2 1005/4885NPC1 2560/4885
US-20040097532-A1 3-Substituted oxindole beta 3 agonists ADRB3, ADRB2, ADRB1 CES1 1668/4885TGM2 4245/4885NPC1 2355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.